Last reviewed · How we verify
Rituximab -CHOP plus Velcade
At a glance
| Generic name | Rituximab -CHOP plus Velcade |
|---|---|
| Sponsor | Lymphoma Study Association |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (PHASE1, PHASE2)
- Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (PHASE2)
- Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma (PHASE2)
- Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE3)
- Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL (PHASE1, PHASE2)
- S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- A Phase I/II Trial of VR-CHOP in Lymphoma Patients (PHASE1, PHASE2)
- A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab -CHOP plus Velcade CI brief — competitive landscape report
- Rituximab -CHOP plus Velcade updates RSS · CI watch RSS
- Lymphoma Study Association portfolio CI